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Breast cancer is one of the most common cancers in women. The
incidence of the disease has increased in recent years in the United
States (Dinse et al, 1999). A substantial portion of the recent trend
may be attributable to screening (Wun et al, 1995), however, the
long-term trend remains unexplained. The established risk factors
for breast cancer account for less than half of all breast cancer
cases and offer few opportunities for intervention (Kelsey et al,
1993; Madigan et al, 1995). 
Recently, non-steroidal anti-inflammatory drugs (NSAIDs)
have received increasing attention due to their potential as chemo-
preventive agents against cancer. Animal studies showed inhibit-
ory effect for NSAID on breast carcinogenesis (Lala et al, 1997;
Robertson et al, 1998). However, several epidemiologic studies
have examined the relation between NSAIDs and breast cancer,
with inconsistent results. In some studies (Laakso et al, 1988;
Gridley et al, 1993) patients with rheumatoid arthritis who use
NSAIDs in high doses for symptom relief had fewer than expected
cases of breast cancer. 
Numerous studies have demonstrated that the level of prosta-
glandin is greater in breast cancer than in normal tissue (Bennett 
et al, 1983). In particular, the inducible form of cyclooxygenase
(COX), the rate-limiting enzyme in prostaglandin biosynthesis
may be overexpressed in breast cancer (Hwang et al, 1998). NSAIDs
are known to block COX activity (Robertson et al, 1998) and thus
become attractive agents for breast cancer prevention. A recent
animal study (Harris et al, 2000) confirmed the chemopreventive
activity of NSAIDs against breast cancer through COX2 blocking.
In this meta-analysis we examined the epidemiological studies on
NSAID use and breast cancer. 
METHODS 
The studies were located via a search of the MEDLINE (from
1966 to 2000) and Cancer Abstract databases (from 1980 to 2000).
Abstracts of research presented at related conferences (Society for
Epidemiologic Research, European Cancer Research, British
Cancer Research, and American Association for Cancer Research)
were also searched. 
Studies were eliminated from the analyses if they included
subjects used in other more-inclusive studies. The estimators of
relative risk and associated variances, which has been adjusted for
the greatest number of confounders, were abstracted and included
in the meta-analysis. 
A series of meta-analyses was conducted and the results were
evaluated in the context of the published literature. The homo-
geneity of the estimators of relative risk was tested using Cochran’s
Q statistics (Cochran, 1954). This is a chi-square test with degrees
of freedom equal to the number of studies minus one, and tests the
null hypothesis that the within-study estimates of relative risk are
homogeneous across studies. The fixed-effect model was used to
obtain the combined estimator of relative risk and its standard
error (SE). The random-effects model (DerSimonian and Laird,
1987) was used in situation when we detected significant hetero-
geneity within the groups of studies. 
The potential for publication bias in published reports was
investigated by constructing funnel plots of log odds ratio against
the size of the study. A Kendall tau rank correlation test (Begg and
Mazumdar, 1994) was used to test for the statistical significance of
publication bias. 
RESULTS 
We identified 15 studies (Friedman and Ury, 1980; Paganini-Hill
et al, 1989; Rosenberg et al, 1991; Thun et al, 1993;
Schreinemachers and Emerson, 1994; Harris et al, 1995;
Rosenberg, 1995; Egan et al, 1996; Harris et al, 1996; Neugut et al,
1998; Coogan et al, 1999; Harris et al, 1999; Cotterchio et al, 2000;
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Langman, 2000; Sharpe et al, 2000) evaluating the association
between NSAIDs and breast cancer that were published between
1980 and 2000. One study (Rosenberg et al, 1991) was excluded
from the analysis because of lack of data on the estimator of rela-
tive risk. The remaining studies were 6 cohort studies (Table 1) and
8 case–control studies (Table 2). The number of cases ranged from
14 to 2414 for cohort studies. For case–control studies the number
of cases ranged from 252 to 5882 and the number of controls
ranged from 42 to 89528. 5 studies (Paganini-Hill et al, 1989;
Thun et al, 1993; Schreinemachers and Emerson, 1994; Egan et al,
1996; Neugut et al, 1998) were restricted to aspirin use and three
studies (Harris et al, 1999; Paganini-Hill et al, 1989; Friedman and
Ury, 1980) provided data stratified by NSAID type. 
Twelve studies reported reduction in the risk of breast cancer
with NSAID use. The estimator of relative risk for cohort studies
ranged from 0.20 to 1.01 and 6 of these estimators were signif-
icant. Only one cohort study (Egan et al, 1996) reported non-
significant increases in the risk of breast cancer with aspirin use.
The estimator of relative risk for case–control studies ranged from
0.57 to 1.00 and 7 of these estimators were significant. None of the
case–control studies reported an increase in the risk of breast
cancer with any NSAID use. 
The results of meta-analyses are presented in Table 3.
Significant heterogeneity was detected among the studies 
(c2 = 53.0, P = 0.001). The combined estimate of relative risk
using the random-effect model was 0.82 (95% CI = 0.75–0.89).
Heterogeneity among studies was significantly reduced when
studies were combined within specific design and type of control.
The combined estimate of relative risk for cohort studies was 0.78
(95% CI 0.62–0.99) with any NSAIDs and was 0.79 (95% 
Table 1 Cohort studies used for meta-analyses of NSAIDs use and breast cancer 
Reference NSAID Ttype Number of cases OR 95% CI 
Harris et al, 1999 Aspirin 76 0.60 0.47–0.77 
Acetaminophen 36 0.84 0.60–1.18 
Ibuprofen 37 0.51 0.36–0.72 
Egan et al, 1996 Aspirin 2414 1.01 0.80–1.27 
Schreinemachers and Everson, 1994 Aspirin 79 0.70 0.50–0.96 
Thun et al, 1993 Aspirin – 0.94 0.80–1.10 
Paganini-Hill et al, 1989 Aspirin 68 0.96 0.75–1.21 
Friedman and Ury, 1980 Aspirin, 2 0.20 0.05–0.80 
Indomethacin 12 0.50 0.28–0.88 
Table 2 Case–control studies used for meta-analyses of NSAIDs use and breast cancer 
Reference Number of cases NSAID type Type of control OR 95% CI 
Sharpe et al, 2000a 5882 Any General population 0.90 0.84–0.97 
Cotterchio et al, 2000 2681 Any General population 0.74 0.65–0.85 
Langman et al, 2000 3105 Any Cancer 1.00 0.92–1.09 
Coogan et al, 1999 6558 Any Cancer 0.80 0.70–1.00 
Non-cancer 0.70 0.60–0.90 
Aspirin Cancer 0.70 0.60–0.90 
Non-cancer 0.70 0.50–0.80 
Neugut et al, 1998 252 Aspirin Non-cancer 0.80 0.35–1.80 
Harris et al, 1996 106 Any General population 0.66 0.52–0.83 
Aspirin, General population 0.69 0.46–0.99 
Ibuprofen General population 0.57 0.36–0.91 
Roenberg, 1995 4485 Any Cancer 0.90 0.60–1.20 
Non-cancer 0.80 0.60–1.00 
Harris et al, 1995 744 Any Cancer 0.96 0.67–1.39 
Non-cancer 0.81 0.63–1.03 
aNested case–control study. 
Table 3 Combined analysis of studies used for meta-analysis of NSAID use and breast cancer 
Reference NSAID type Number of studies Test of heterogeneity  OR 95% CI 
c2 P value
All studies Any 16 38.1 0.001 0.80 0.73–0.87 
Cohort studies Any 6 22.8 <0.001 0.78 0.62–0.99 
Aspirin 6 17.8 <0.001 0.79 0.59–1.06 
Case–control 
All Any 10 15.2 0.09 0.83 0.79–0.88 
Cancer 3 1.0 0.621 0.84 0.72–0.97 
Non-cancer 7 14.2 0.03 0.79 0.72–0.86 
All Aspirin 4 0.10 0.99 0.70 0.61–0.81 1190 SA Khuder and AB Mutgi 
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CI = 0.59–1.06) for aspirin use. The case–control studies were re-
latively homogeneous within cancer and non-cancer controls. The
combined estimate of relative risk for these studies was 0.87 (95%
CI 0.84–0.91) with any NSAID and was 0.70 (95% CI =
0.61–0.81) for aspirin use. The combined estimate of relative risk
for studies with non-cancer controls was 0.79 (95% CI 0.72–0.86)
and was 0.96 (95% CI = 0.89–1.03) for studies with cancer
controls. 
Table 4 Duration of use reported in studies used in the meta-analysis of NSAID use and breast cancer 
Study Measure Duration OR 95% CI 
Coogan et al, 1999a NSAID regular use (years) begun ³ 1 year before admission Never 1 – 
< 1 0.90 0.50–1.70 
1–< 2 1.10 0.70–1.70 
2–< 5 0.70 0.50–1.00 
5–< 10 0.70 0.40–1.00 
10–< 20 0.70 0.40–1.10 
20+ 0.60 0.30–1.00 
Unknown 0.40 0.20–0.70 
Harris et al, 1995 NSAID use, years 0 1 – 
1–4 1.09 0.80–1.50 
³5 0.63 0.50–0.90 
Egan et al, 1996 Aspirin use, years <5 0.89 0.76–1.05 
5–9 0.98 0.81–1.19 
10–19 1.11 0.85–1.46 
³20 1.00 0.71–1.41 
Harris et al, 1996 NSAID use, years <5 0.65 0.47–0.91 
³5 0.60 0.40–0.91 
Langman et al, 2000 Prescription of NSAID before diagnosis, months 13–24 1.03 0.93–1.13 
25–36 1.00 0.91–1.11 
Sharpe et al, 2000 Highest level of NSAID exposure before diagnosis, years 1/2 1.05 0.91–1.23 
1/2–1 1.20 1.02–1.40 
2–5 0.76 0.63–0.92 
6–10 1.13 0.92–1.39 
11–15 0.83 0.63–1.11 
aSignificant dose–response relationship. 
Table 5 Frequency of NSAID use in studies used in the meta-analysis of NSAID use and breast cancer 
Study Measure Frequency OR 95% CI 
Sharpe et al, 2000a Sum of NSAID mg day–1 dispensed ÷ maximum mg day–1 0 1.0 – 
recommended (Sp) in 2–5 years before diagnosis
0 < Sp ≤ 1 0.93 0.85–1.01 
0.1 < Sp ≤ 0.3 0.91 0.79–1.06 
Sp >0.3 0.76 0.63–0.92 
Egan et al, 1996 Number of aspirins per week 0 1.00 – 
1–3 0.99 0.89–1.11 
4–6 0.94 0.80–1.10 
7–10 1.00 0.84–1.20 
11–14 1.11 0.91–1.37 
>14 1.05 0.89–1.23 
Paganini-Hill et al, 1989 Aspirin use None 1 – 
<daily 0.95 0.68–1.34 
daily 0.96 0.69–1.34 
Harris et al, 1996 NSAID dose/week 3–6 0.73 0.46–1.13 
³7 0.63 0.49–0.81 
Thun et al, 1993 Aspirin frequency/month occasionally 0.93 0.73–1.19 
1–15 0.98 0.76–1.26 
16+ 0.88 0.62–1.24 
Harris et al, 1999 NSAID pills per week 0 < 1 1.00 – 
1–3 0.64 0.50–0.82 
³4 0.57 0.44–0.74 
Langman et al, 2000 Number of prescriptions of NSAID received in 13–24 months before diagnosis 0 1 – 
1 0.99 0.87–1.13 
2–6 0.96 0.83–1.11 
³7 1.10 0.92–1.30 
aSignificant dose–response relationship. NSAID use and breast cancer 1191
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Six studies provided results on duration of use of aspirin and that
of other NSAIDs (Table 4). 9 studies provided results stratified by
measures of NSAID use (Table 4). The risk reduction for highest
duration of use (20+ years) ranged from 40% (Coogan et al, 1999)
to zero (Egan et al, 1996). Trend tests for dose–response relations
in only one of these studies was significant. The available data in
Table 4 are insufficient to estimate the combined dose–response
effect for duration of use of any particular types of NSAID. 
Seven studies provided results on frequency of use of aspirin and
that of other NSAID (Table 5). In one study (Harris et al, 1999) four
or more pills of NSAID per week was associated with a 43% reduc-
tion in the risk of breast cancer (RR = 0.57, 95% CI 0.44–0.74). In
another study (Paganini-Hill et al, 1989) daily use of aspirin was
associated with only 4% reduction in the estimated risk of breast
cancer (RR = 0.96, 95% CI 0.69–1.34). The available data in Table 5
are insufficient to estimate the combined dose–response effect for
frequency of use of any particular types of NSAID. 
There was no evidence of publication bias in studies included in
this meta-analysis. The Kendall tau correlation coefficient for the
standard error and the standardized log odds ratio was 0.96 
(P = 0.34). 
DISCUSSION 
This meta-analysis showed that NSAID use may decrease the risk
of breast cancer. This is evident by the consistently reduced relat-
ive risk in the majority of studies included in the analysis. The
effect observed was similar in most studies regardless of design or
type of cases (incident or fatal cases). The only negative study
(Egan et al, 1996) may have been confounded by reproductive
factors. In this meta-analysis, regular use of NSAIDs was
associated with an 18% reduction in the risk of breast cancer.
The reduction in risk was higher in cohort studies (21%)
than case–control studies (13%). Within case–control studies, the
reduction in risk was smaller in studies with cancer controls
than in those with non-cancer controls. Although this finding is 
consistent with studies on NSAID use and colon cancer (Harris 
et al, 1995), it may argue against a true effect against breast cancer
since this should be consistent across control groups. It is possible
that some cancer subtypes (for example, gastrointestinal) were
related to NSAID use and these patients discontinued the drug. If
so this may overestimate the odds ratio and may bias the estimate
of relative risk away from the null value. It is possible that the
results of these studies are biased by a higher prevalence of pre-
existing medical conditions commonly associated with NSAID
use among non-cancer controls. On the other hand population-based
case–control studies (Neugut et al, 1998) used as control subjects
who underwent screening mammography, and their use of NSAID
could have overestimated the prevalence of use in the study base. 
With regard to type of NSAID, aspirin was the major type used
in the studies included in this meta-analysis. In general, the reduc-
tion in risk of breast cancer with aspirin use was similar to other
NSAID type. Two studies reported higher reduction in risk with
ibuprofen in comparison to aspirin. However, available data were
not adequate enough to test this in a meta-analysis. 
Nine studies evaluated dose–response relation of NSAID use
and breast cancer but only two studies reported significant dose–
response relation for duration (Coogan et al, 1999) and frequency
(Sharpe et al, 2000) of NSAID use. In one study (Coogan et al,
1999) the highest reduction in breast cancer risk was reported for
the category ‘unknown years of use’. 
Although publication bias is possible because of the possibility 
of failure of investigators to submit negative results or failure of 
journals to publish negative studies our analysis did not suggest this. 
The effect of NSAIDs on breast cancer risk reduction is biolo-
gically plausible. A number of animal studies have suggested a
protective effect of NSAIDs against mammary cancer. A potential
mechanism for anti-tumour effect of NSAIDs involves inhibition
of the synthesis of prostaglandins. NSAIDs block the enzyme
cyclooxygenase and in turn inhibit prostaglandin biosynthesis.
Prostaglandins may serve as cofactors in carcinogenesis 
with potential effects ranging from direct mutagenesis to 
tumour promotion and immune suppression (Lupulescu, 1978;
Mellemkjaer et al, 1996). One study (McCormick and Wilson,
1986) suggests that the cancer inhibitory effects of NSAIDs may
be independent of their effects on prostaglandin synthesis. There is
evidence from animal studies that indomethacin inhibits the
effects of oestrogen in the pituitary gland (Neugut et al, 1998). In-
vitro studies of human breast cancer cells indicate that acetylsali-
cylic acid may inhibit direct binding of oestradiol to oestrogen
receptor (Thompson et al, 1995). 
The majority of studies included in this meta-analysis adjusted
for known risk factor for breast cancer. Our inclusion of estimators
of relative risk, which were adjusted for the greatest number of
confounders, would have reduced the possibility of confounding
effect. The combined estimate of this study supports a protective
effect for NSAIDs against breast cancer. Other support for the
protective effect of NSAIDs against breast cancer comes from
studies on patients with rheumatoid arthritis who use NSAIDs in
high doses for symptom relief. 2 studies (Gridley et al, 1993;
Baron, 1995) reported that these patients had less than expected
occurrence of breast cancer. The risk pattern for NSAID users
found in this meta-analysis is consistent with the pattern found in
studies on patients with rheumatoid arthritis. 
The limitations of this study stem from the studies included in
the meta-analysis. All the studies included are observational
studies and therefore subject to biases. Some are case–control
studies and we cannot rule out the possibility of selection and
information biases. It is possible that the relation between NSAIDs
and breast cancer may reflect a recall bias by the cases or controls.
Misclassification of exposure is a potential problem in observa-
tional epidemiological studies. None of the studies included in this
meta-analysis utilized an objective method of exposure assess-
ment. In all studies the NSAID use was self-reported and therefore
subject to recall bias. These drugs are often taken sporadically in a
pattern of intake that may be difficult to remember or summarize
for some subjects. For example, some widely used brands or
combination product may not be recognized as containing aspirin
(Harris et al, 1995). It is possible that NSAID use may reflect a
health consciousness among the control group. However, Harris 
et al (1995) reported no association between NSAID use and level of
education, which can be taken as a proxy for health consciousness. 
Currently known risk factors account for less than half of all
breast cancer cases and offer limited opportunities for interven-
tion. Therefore, any preventive measure identified will be import-
ant. This meta-analysis suggests that NSAIDs have a weak
chemopreventive value against breast cancer. However, we cannot
rule out the possibility of an alternate explanation for this finding
due to the limitations of the studies included in the analysis. 
There is a need for more studies that prospectively evaluate the
reduction in risk of breast cancer utilizing a better measure of
NSAID dose. There is a need to establish whether NSAIDs are1192 SA Khuder and AB Mutgi 
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efficacious in preventing breast cancer and type and optimal dose.
This can be accomplished using a randomized clinical trial on
different types of NSAID. 
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